Ma L, Xing HC. Elimination of hepatitis B as a public health threat: Addressing the challenge and taking action. World J Hepatol 2024; 16(11): 1361-1364 [DOI: 10.4254/wjh.v16.i11.1361]
Corresponding Author of This Article
Hui-Chun Xing, Doctor, MD, Chief Doctor, Professor, Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. huichunxing@126.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Nov 27, 2024; 16(11): 1361-1364 Published online Nov 27, 2024. doi: 10.4254/wjh.v16.i11.1361
Elimination of hepatitis B as a public health threat: Addressing the challenge and taking action
Lei Ma, Hui-Chun Xing
Lei Ma, Hui-Chun Xing, Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Author contributions: Ma L contributed to wring this manuscript; Xing HC designed the overall concept and outline of the manuscript, review of all literatures, proofread and review the full text.
Supported bythe National Key Research and Development Program of China, No. 2022YFC2304505 and No. 2021YFC2301801; the Beijing Municipal of Science and Technology Major Project, No. 20220383ky; and Capital’s Funds for Health Improvement and Research of China, No. 2024-1-2181.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Chun Xing, Doctor, MD, Chief Doctor, Professor, Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. huichunxing@126.com
Received: August 5, 2024 Revised: September 30, 2024 Accepted: October 15, 2024 Published online: November 27, 2024 Processing time: 93 Days and 2.9 Hours
Core Tip
Core Tip: Currently, the rates of diagnosis and treatment are significantly low, particularly in resource-limited developing countries. Therefore, immediate action must be taken without any delay. In the expanding screening population, it is essential to prioritize hepatitis B surface antigen testing for all high-risk groups and utilize high sensitivity hepatitis B virus DNA testing to detect low-level viremia, which is associated with the prognosis of hepatitis B virus infection. Some patients in the indeterminate phase require immediate antiviral treatment. Reducing the cost and improving access to screening and treatment are also crucial, highlighting the need for collaboration between governments, healthcare organizations, and pharmaceutical companies. Integrating the delivery of care, prevention, and treatment for hepatitis B into existing health services can streamline testing, care, and treatment for hepatitis B.
